‌

US Patent 10307371 Rapamycin for the treatment of lymphangioleiomyomatosis

Patent 10307371 was granted and assigned to AI Therapeutics on June, 2019 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

0

Patent attributes

Patent Applicant

OrphAI Therapeutics

0

Current Assignee

OrphAI Therapeutics

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Henri Lichenstein0

Lawrence S. Melvin, Jr.0

Thomas Armer0

Jonathan M. Rothberg0

Date of Patent

June 4, 2019

0

Patent Application Number

158030050

Date Filed

November 3, 2017

0

Patent Citations Received

US Patent 11491143 Inhalable rapamycin formulation for the treatment of pulmonary hypertension

0

US Patent 11648199 Inhalable rapamycin formulation for treating age-related conditions

0

US Patent 11744797 Rapamycin for the treatment of lymphangioleiomyomatosis

Patent Primary Examiner

Melissa L Fisher

0

Patent abstract

The present invention relates to methods and compositions for treating lymphangioleiomyomatosis in a human subject in need of such treatment. The methods comprise administering to the subject via inhalation an aerosol composition comprising rapamycin or a prodrug or derivative (including analog) thereof.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10307371 Rapamycin for the treatment of lymphangioleiomyomatosis

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.